DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hn8db4/pharmapoint) has announced the addition of the "PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022" report to their offering.
The French market will also see the entry of several pipeline drugs with novel, first-in-class mechanisms of action, such as CNV-2197944 (PDN and PHN) and CNV-1014802 (TN), which will add patient share.
As is the case in the global market, the overall NP market in Germany will show growth over the forecast period that will be driven predominantly by growth in the PDN segment of the market.
Due to the delayed launch of Versatis in Italy, the dominant NP drug classes in the Italian NP market in terms of market share are slightly different compared with the US and the rest of the EU. Similar to Italy, the overall NP market in Spain will show growth over the forecast period that will be driven predominantly by the PDN and PHN segments.
Surprisingly, in the UK, the order of the three leading NP products is very different compared with the US and the rest of the EU.
- Overview of Neuropathic Pain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Neuropathic Pain market.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/hn8db4/pharmapoint